257 results on '"Schmidt-Erfurth"'
Search Results
2. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
3. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
4. Application of Automated Quantification of Fluid Volumes to Anti–VEGF Therapy of Neovascular Age-Related Macular Degeneration
5. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group
6. TENAYA and LUCERNE
7. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
8. Fully Automated Detection and Quantification of Macular Fluid in OCT Using Deep Learning
9. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies
10. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials
11. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD
12. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies
13. Pigment Epithelial Detachment Followed by Retinal Cystoid Degeneration Leads to Vision Loss in Treatment of Neovascular Age-Related Macular Degeneration
14. Deliberations of an International Panel of Experts on OCT Angiography Nomenclature of Neovascular Age-Related Macular Degeneration
15. Intravitreal Aflibercept for Diabetic Macular Edema
16. Morphologic Parameters Relevant for Visual Outcome During Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration
17. Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema: The RESTORE Extension Study
18. Refractive Changes after Pharmacologic Resolution of Diabetic Macular Edema
19. Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration: Ninety-Six–Week Results of the VIEW Studies
20. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study
21. Influence of the Vitreomacular Interface on Outcomes of Ranibizumab Therapy in Neovascular Age-related Macular Degeneration
22. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
23. One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
24. Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration: Twelve-month MONT BLANC Study Results
25. The RESTORE Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema
26. The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema
27. A Systematic Comparison of Spectral-Domain Optical Coherence Tomography and Fundus Autofluorescence in Patients with Geographic Atrophy
28. Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
29. High-Resolution Optical Coherence Tomography after Surgery for Vitreomacular Traction: A 2-Year Follow-up
30. Effect of Retinal Photocoagulation on Intraretinal Lipid Exudates in Diabetic Macular Edema Documented by Optical Coherence Tomography
31. High-Resolution Imaging of the Human Retina In Vivo after Scatter Photocoagulation Treatment Using a Semiautomated Laser System
32. In Vivo Retinal Morphology after Grid Laser Treatment in Diabetic Macular Edema
33. Neovascular Age-related Macular Degeneration: Intraocular Cytokines and Growth Factors and the Influence of Therapy with Ranibizumab
34. Association of Retinal Sensitivity and Morphology during Antiangiogenic Treatment of Retinal Vein Occlusion over One Year
35. Optical Coherence Tomographic Hyperreflective Foci: A Morphologic Sign of Lipid Extravasation in Diabetic Macular Edema
36. A Systematic Correlation of Angiography and High-Resolution Optical Coherence Tomography in Diabetic Macular Edema
37. Time Course of Morphologic Effects on Different Retinal Compartments after Ranibizumab Therapy in Age-related Macular Degeneration
38. Randomized Multicenter Trial of More Intense and Standard Early Verteporfin Treatment of Neovascular Age-Related Macular Degeneration
39. Deliberations of an International Panel of Experts on OCT Angiography Nomenclature of Neovascular Age-Related Macular Degeneration
40. Verteporfin Therapy Combined with Intravitreal Triamcinolone in All Types of Choroidal Neovascularization due to Age-Related Macular Degeneration
41. HAWK and HARRIER
42. Time Course and Morphology of Vascular Effects Associated with Photodynamic Therapy
43. Comparison of Early Retreatment with the Standard Regimen in Verteporfin Therapy of Neovascular Age-Related Macular Degeneration
44. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
45. Reply
46. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group
47. Effects of verteporfin therapy on central visual field function
48. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin
49. Characterization of leakage activity in exudative chorioretinal disease with three-dimensional confocal angiography
50. Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.